Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases

Carlo Baronci, Angelamaria Petrone, Crescenzo Miano, Alessandra Lombardi, Maurizio Caniglia, Lidia Angiolina Russo, Matteo Luciani, Rita Maria Pinto, Ippolita Rana, Roberta Caruso, Giulio De Rossi

Research output: Contribution to journalArticlepeer-review


Acute idiopathic thrombocytopenic purpura (AITP) in children is generally a benign disease with a high frequency of spontaneous remission. Nevertheless the debate over treating or not is still open, because of the high risk of hemorrhage as long as the platelet count remains below 20 x 109/l. We have retrospectively evaluated 120 pediatric cases from our center, receiving different treatments at diagnosis: no treatment (76); IVIG: 400 mg/kg/d for 5 days (28); continuous oral PDN: 1-1.5 mg/kg/d for at least two weeks (16). No patients had been previously treated for AITP. Follow-up is up to fifty months. We found no significant differences as to the percentage of responses among the three groups. We conclude that waiting without treatment is safe and appropriate in most cases; whether the hemorrhagic risk suggests treatment, standard dose continuous oral PDN and IVIG may be equally effective, but IVIG may achieve a significantly faster rise in the platelet count. The timing of treatment and the cost/benefit ratio are discussed.

Original languageEnglish
Pages (from-to)457-461
Number of pages5
JournalAnnali dell'Istituto Superiore di Sanita
Issue number4
Publication statusPublished - 1998


  • Immune thrombocytopenic purpura
  • Immunoglobulins
  • Steroid

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Treatment of acute idiopathic thrombocytopenic purpura in children. A retrospective evaluation of 120 cases'. Together they form a unique fingerprint.

Cite this